Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review3060 has been discontinued.
View all Glutamate (Metabotropic) Group I Receptors products.Potent, non-competitive mGlu1 receptor antagonist that displays 34-fold selectivity over mGlu5 (IC50 values are 10 and 342 nM respectively). Displays no significant activity at a range of other GPCRs, ion channels and transporters. Exhibits analgesic effects; decreases mechanical allodynia in models of neuropathic pain. Also impairs cognitive function.
M. Wt | 343.45 |
Formula | C17H21N5OS |
Storage | Store at RT |
Purity | ≥98% (HPLC) |
CAS Number | 869802-58-4 |
PubChem ID | 11559235 |
Smiles | O=C(N(N4CCCCCC4)C=N3)C2=C3C1=C(N(C)C)C=CN=C1S2 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Zheng et al (2005) Structure-activity relationship of triazafluorenone derivatives as potent and selective mGluR1 antagonists. J.Med.Chem. 48 7374 PMID: 16279797
El-Kouhen et al (2006) Blockade of mGluR1 receptor results in analgesia and disruption of motor and cognitive performances: effects of A-841720, a novel non-competitive mGluR1 receptor antagonist. Br.J.Pharmacol. 149 761 PMID: 17016515
More et al (2007) Comparison of the mGluR1 antagonist A-841720 in rats models of pain and cognition. Behav.Pharmacol. 18 273 PMID: 17551319
View all Glutamate (Metabotropic) Group I Receptor Antagonists
Keywords: A 841720, A 841720 supplier, Selective, mGlu1, mGluR1, antagonists, mGlur, Group, I, Receptors, Glutamate, Metabotropic, A841720, (Metabotropic), 3060, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for A 841720 include:
Rojas et al (2013) Activation of group I metabotropic glutamate receptors potentiates heteromeric kainate receptors. Mol Pharmacol 83 106 PMID: 23066089
Veettil et al (2014) Glutamate secretion and metabotropic glutamate receptor 1 expression during Kaposi's sarcoma-associated herpesvirus infection promotes cell proliferation. PLoS Pathog 10 e1004389 PMID: 25299066
There are currently no reviews for this product. Be the first to review A 841720 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.